Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab + MRG002 in HER2+ Cancer of Unknown Primary
NCT06869174Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Countries
- 1
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Drugs
- pucotenlimabMRG002
- Conditions
- cancer of unknown primary (CUP)
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab and MRG002 in cancer of unknown primary (CUP). Primary endpoint: Overall Response Rate at 12 months. Planned start Mar 2025; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Treatment Arm
Pucotenlimab combined with MRG002
03
Who it enrols
Adult patients with HER2-positive (IHC 2+ or 3+) cancer of unknown primary who have received at least one prior line of systemic therapy.
04
Endpoints
Primary
Overall Response Rate
Beyond the preview
Go deeper on NCT06869174.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06869174.